The detection of up-regulated anti-thyroid antibodies and autoimmune thyroid diseases in patients with autoimmune encephalitis: a retrospective study of 221 patients
ATAbs (anti-thyroglobulin antibodies [TgAb], anti-thyroid peroxidase anti-bodies [TPOAb]) -positive and/or AITD (Hashimoto’s thyroiditis and Graves’ disease) patients with symptomatic encephalopathy should undergo proper surveillance for AE. Moreover, low fT3 could serve as a possible predictor of poor short-term outcome in AE, thereby suggesting that monitoring of thyroid function in AE may be necessary.
Thyroid antibodies: the end of an era?
This scientific commentary refers to ‘Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis’, by Valencia-Sanchez et al.
In the interest of our patients, we must recognize the new evidence that demonstrates that the diagnostic utility of thyroid antibody testing is limited in the evaluation of autoimmune neurologic conditions. Its role is, at best, limited to demonstrating a potential propensity to systemic autoimmunity. Cessation of thyroid antibody testing in the evaluation of suspected autoimmune encephalitis and encephalopathy will hopefully reduce harm from misdiagnosis and unwarranted treatment, and minimize financial toxicity related to unnecessary interventions.
Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis
We aimed to retrospectively review 144 cases referred with suspected Hashimoto encephalopathy over a 13-year period, and to determine the clinical utility of thyroid antibodies in the course of evaluation of those patients.
In total, 73% of the patients referred with suspected Hashimoto encephalopathy had an alternative non-immune-mediated diagnosis, and more than half had no evidence of a primary neurological disorder. Thyroid antibody prevalence is high in the general population, and does not support a diagnosis of autoimmune encephalopathy in the absence of objective neurological and CNS-specific immunological abnormalities. Thyroid antibody testing is of little value in the contemporary evaluation and diagnosis of autoimmune encephalopathies.
In our experience within our specialty referral practice, the diagnosis of HE/SREAT is assigned to a variety of patients with elevated thyroid antibody values and diverse neuropsychiatric symptomatic presentations, generally without objective demonstration of encephalopathy, CNS inflammation or objective steroid response.
We conclude that thyroid antibodies have served their time as diagnostic biomarkers in autoimmune encephalopathy well, but their role in the evaluation of autoimmune encephalopathy is likely redundant at this point, and certainly less specific than a clinical history of autoimmune disease and neural-specific antibodies. Our experience indicates that a diagnosis of HE/SREAT is often given to patients presenting with cognitive symptoms and a variety of neurological and non-neurological complaints, in the setting of elevated thyroid antibodies in serum without objective cognitive abnormalities. The utility of testing for thyroid antibodies seems questionable in the modern era which has brought availability of validated clinical criteria and advanced neuroimmunologic diagnostics. Over diagnosis of autoimmune encephalopathy brings undesired consequences such as iatrogenic harm, cost of unnecessary immunosuppressive therapies and delayed diagnosis of the correct neurological disorder. As always, test results need to be interpreted in the context of detailed clinical history and examination.
Hashimoto’s Encephalopathy: A Rare Cause of Seizure-like Activity
Case study conclusions: HE is rare and can present with a variety of clinical presentations. It should be considered as a differential for a patient presenting with unexplained cognitive impairment. It is crucial to detect and treat HE, as early treatment with steroid therapy has a good prognosis. A screening test of thyroid function test and TPOAb should be incorporated in the confusion screen for patients presenting with acute or subacute cognitive impairment. Other diagnoses should also be excluded with a full workup that includes labs, CSF studies, EEG, and imaging. Treatment with steroids should be considered, especially in patients with seizures that do not respond with anti-epileptics, along with the treatment of underlying thyroid disorder.
Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis and thyroid antibodies
Highly Recommended for All Patients who Have received a diagnosis of Hashimoto’s Encephalitis
A retrospective review of cases referred with suspected Hashimoto encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis, over a 13 year period. The final study included 144 patients. After clinical and testing evaluations had been completed, 39/144 patients (27%) were assigned a diagnosis of an autoimmune CNS disorder (Table 2), and 105/144 (73%) were given an alternative clinical diagnosis.
Hashimoto's encephalopathy – presenting with epilepsia partialis continua and a frontal lobe lesion
HE, as our case illustrates, can present as progressive EPC with a focal cortical lesion.
Rare case of Hashimoto's encephalitis mimicking grief reaction
(SREAT) in a Patient Misdiagnosed with Alzheimer’s Disease
Hashimoto encephalopathy: A study on radiological and electrophysiological correlation
Hashimoto Encephalopathy or Neurosarcoidosis? Case Report
Two patients with Hashimoto's encephalopathy and uncontrolled diabetes successfully treated with levetiracetam
Hashimoto’s Encephalopathy: case report
MRI Findings of Two Patients With Hashimoto Encephalopathy
There is a wide range of reported neuroimaging abnormalities in HE. We present two cases of HE that demonstrate this fluctuation and variability. HE is often misdiagnosed and can be mistaken for other autoimmune encephalitides or viral encephalitis. As such it is important to understand the neuroimaging features that can potentially differentiate these entities. MRI is valuable in the setting of this disease not just for diagnosis but to evaluate evolution and resolution of the abnormalities.
Hashimoto encephalopathy in the 21st century
This important paper highlights the difficulties in using TPO antibodies as a marker of CNS autoimmunity, particularly as the antibodies do not bind to neuronal tissue. It also highlights that current criteria do not differentiate steroid responders from non-responders.
It also leaves several questions: what are the mechanisms behind HE? What markers will help us identify the 30% of patients that need treatment, and spare the others the risks of high dose steroids? Listen to the corresponding podcast with Drs. Dalmau and Graus in our podcast section.